PMLive Media Talks About Noctura 400
Sight-saving MedTech sleep mask could save the NHS multimillions
Commenting on the treatment’s benefits Mr. Ulrich Meyer-Bothling, Consultant Ophthalmic Surgeon at Ashford and St Peter’s Hospitals NHS Foundation Trust said:
“The Trust’s decision to offer the sleep mask as part of its diabetic retinopathy pathway is great news for patients and the NHS alike. For patients, it represents a pain-free treatment option for their condition. It is non-invasive, and they are, in effect, treated whilst they sleep. It also doesn’t require patients to attend the hospital as frequently, giving them more of their time back. It represents a gentler approach to treating or even preventing diabetic retinopathy and diabetic macular oedema. I’m proud that most of the patients I have treated with the mask have shown stabilization and improvement in their diabetic eye disease.”
Richard Kirk, Chief Executive of PolyPhotonix, said:
“For the NHS, treating diabetic retinopathy patients with the Noctura 400 sleep mask represents a cost-effective alternative to existing treatments. At a time when our healthcare budgets are already stretched, adding the sleep mask to existing care pathways makes sound financial sense in helping healthcare services recover from the pandemic and freeing up hospital appointments for those in greater need of emergency care. Most importantly, it prevents problems before they arise and enables doctors to improve patient care.”
The adoption of PolyPhotonix’s Noctura 400 sleep mask by Ashford and St Peter’s NHS Foundation Trust is set to benefit NHS patients suffering from diabetic retinopathy. The innovative sleep mask has been shown to improve patients’ visual acuity and could save the NHS millions of pounds each year. The mask has demonstrated improvement and stabilization of diabetic eye disease in 96% of patients, making it an early-stage non-invasive alternative to current, later-stage invasive treatments such as eye injections for patients with the condition. If adopted across the NHS, the sleep mask could deliver cost savings estimated in excess of £180m per year and reduce hospital clinic appointments and the use of eye injection treatments at a later stage. The mask delivers a precise level of light at a particular wavelength during a patient’s normal hours of sleep to prevent the eyes’ increased demand for oxygen at night and reduce the damaging effects of diabetic retinopathy on patients’ eyesight.